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ABSTRACT
Introduction: The aim of the present study was
to evaluate the 24-h efficacy, tolerability, and
ocular surface health with preservative-free (PF)
tafluprost and a PF triple drug regimen
comprising tafluprost and dorzolamide/timolol
fixed combination (DTFC) in open-angle
glaucoma patients who were insufficiently
controlled with preserved branded or generic
latanoprost monotherapy and who exhibited
signs or symptoms of ocular surface disease
(OSD).
Methods: Prospective, observer-masked,
crossover, comparison. Eligible consecutive
open-angle glaucoma patients were
randomized to either PF tafluprost or the triple
PF regimen for 3 months. They were then
crossed over to the opposite therapy for
another 3 months. At the end of the
latanoprost run-in period and after each PF
treatment period, patients underwent habitual
24-h intraocular pressure (IOP) monitoring with
Goldmann tonometry in the sitting position (at
10:00, 14:00, 18:00, and 22:00) and Perkins
tonometry in the supine position (at 02:00 and
06:00). Tolerability and selected ocular surface
parameters were evaluated at baseline and the
end of each treatment period.
Results: Forty-three open-angle glaucoma
patients completed the trial. Mean 24-h IOP
on preserved latanoprost was 22.2 ± 3.9 mmHg.
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Compared with latanoprost monotherapy, PF
tafluprost obtained a greater reduction in mean,
peak, and fluctuation of 24-h IOP including the
02:00 and 06:00 time points (P\0.05). With
the exception of 24-h fluctuation, the triple PF
regimen provided significantly lower IOP
parameters than latanoprost or PF tafluprost
(P\0.001). Finally, PF tafluprost therapy
displayed significantly improved tear film
break-up times (6.7 vs 6.0 s), corneal staining
(1.3 vs 2.2), and Schirmer I test results (9.1 vs
8.2 mm) compared with the preserved
latanoprost baseline (all P\0.01). The triple
PF regimen demonstrated similar tear film
break-up times (6.1 vs 6.0 s) and Schirmer I
test results (8.2 vs 8.2 mm) to latanoprost, but
revealed a significant improvement in the
corneal stain test (1.7 vs 2.2; P\0.001).
Conclusions: In this trial PF tafluprost therapy
provided statistically greater 24-h efficacy and
improved tolerability compared with preserved
latanoprost. The combination of PF tafluprost
and PF dorzolamide/timolol fixed combination
was statistically and clinically more efficacious
than both monotherapies and demonstrated
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INTRODUCTION
A meaningful intraocular pressure (IOP)
reduction remains the mainstay of current
glaucoma management [1–3]. Although
therapy ideally commences with a
monotherapy agent, inevitably monotherapies
will not suffice for most patients in the long
term [3]. Therefore, stepwise medical therapy is
often necessary [1, 3]. It has been established,
however, that combined antiglaucoma therapy
can adversely influence adherence, tolerability,
and ocular tissue health [4–6]. These parameters
markedly reduce the success of long-term
medical therapy [6, 7]. Treatment advances
have been introduced to facilitate the success
of combined therapy in real life. For instance,
fixed combinations (FCs) were introduced to
enhance convenience by minimizing the
number of daily drops, improve adherence,
enhance tolerability, and conceivably improve
long-term ocular outcomes [1, 8–10].
In glaucoma a direct consequence of lifelong
combined medical therapy is the cumulative
toxic effect of preservatives upon and within
ocular tissues [10]. The most common
preservative contained in glaucoma
medications is benzalkonium chloride (BAK), a
quaternary ammonium salt that acts as a
detergent by disrupting lipid membranes and
denaturing proteins [11]. There is convincing
scientific evidence to suggest that BAK elicits
substantial toxic damage upon the ocular
surface [11–14]. A range of BAK-related ocular
surface findings include tear film instability
[14, 15], corneal and conjunctival epithelial
apoptosis [15], increased tear osmolarity [16],
and meibomian gland dysfunction [10]. These
signs of ocular surface disease (OSD) cause a
variety of ocular symptoms that adversely
impact quality of life and ultimately reduce
long-term adherence and success of glaucoma
therapy [17, 18]. Moreover, chronic exposure to
preservatives (especially BAK) may elicit ocular
tissue inflammatory and fibrotic reactions that
can undermine the potential long-term success
of future glaucoma surgery [19–21]. Lastly, there
is growing suspicion that BAK can also damage
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deeper ocular tissues (e.g., the trabecular
meshwork) [10, 22]. Importantly,
preservative-related ocular tissue toxicity is
cumulative; therefore, patients receiving
combined therapies with multiple preserved
drops over a long period may be particularly
prone to OSD [10]. It is now well documented
that the majority of chronically treated
glaucoma patients exhibit signs or symptoms
of OSD [12–14]. Simplifying stepwise therapy by
employing FCs and switching when possible to
preservative-free (PF) medications may
ameliorate these toxic effects and enhance the
success of long-term stepwise therapy.
Branded or generic latanoprost 0.005%
containing BAK is currently the most popular
first-choice monotherapy in Europe for patients
with ocular hypertension or glaucoma [23].
However since the branded latanoprost
formulation contains a high concentration of
BAK (0.02%) [24], there will be, over time, a
growing number of patients with signs/
symptoms of OSD. The problem may become
more acute when latanoprost-treated patients
with signs or symptoms of OSD require
adjunctive therapy. Currently there is a
paucity of clinical information on the impact
upon 24-h IOP efficacy and the comparative
ocular surface damage, assessed with validated
ocular surface metrics, when we switch patients
with signs or symptoms of OSD from preserved
latanoprost to a PF medication. Established PF
treatment options include tafluprost 0.0015%
and dorzolamide 2%/timolol 0.5% fixed
combination (DTFC). To the best of our
knowledge there is no published evidence on
the 24-h efficacy, tolerability, and ocular surface
health with the use of a triple PF therapy in
glaucoma. Therefore, the main objective of the
current study was to evaluate the 24-h efficacy
and ocular surface health of PF tafluprost and a
triple PF regimen (tafluprost and DTFC) in
open-angle glaucoma patients insufficiently
controlled on branded or generic latanoprost




All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Declaration of Helsinki (1964), as revised in
2013. The study was also approved by the
University Bioethics Committee. Written
informed consent was obtained from all
participants prior to any study-related
procedure. The study was registered with
ClinicalTrials.gov (NCT02802137).
This was a 3-month prospective,
observer-masked, crossover, comparative study
conducted at an academic glaucoma service.
The trial enrolled consecutive patients with
signs or symptoms of OSD and
early-to-moderate open-angle glaucoma
(primary open-angle, exfoliative, or
pigmentary glaucoma) who were insufficiently
controlled after at least 3 months of therapy
with branded or generic BAK-preserved
latanoprost monotherapy and demonstrated a
latanoprost-treated morning (10:00 ± 1 h) IOP
greater than 20 mmHg and at least 20% IOP
reduction from untreated baseline in two
separate visits. To be considered for inclusion,
glaucoma patients must have shown an
untreated morning IOP between 25 and
39 mmHg at 10:00 (±1 h) in the clinic.
Additional eligibility criteria were age between
21 and 85 years; mild to moderate
glaucomatous disc damage and visual field loss
(less than -12 dB mean deviation visual field
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loss attributed to glaucoma and 0.8 or
better/less vertical cup-to-disc ratio), and visual
acuity better than 0.1 in the study eye. The
diagnosis of open-angle glaucoma was made by
a senior glaucoma expert (AGK) on the basis of
the European Glaucoma Society criteria [1].
Study patients had to exhibit reliable
perimetry (at least two visual fields with less
than 20% fixation losses, false positives, or false
negatives in both eyes) [25] and be able to
understand study instructions, comply with
study medication usage, and be willing to
attend all follow-up visits. A comprehensive
clinical examination that included slit-lamp
biomicroscopy, Goldmann applanation
tonometry, gonioscopy, dilated fundoscopy
with a 60-diopter lens, ultrasound pachymetry,
and Humphrey 24-2 SITA Standard visual field
testing (Carl Zeiss Meditec, Dublin, CA) was
performed prior to enrollment.
Exclusion criteria were a previous history of
less than 10% IOP decrease on any
antiglaucoma medication; signs of ocular
infection (except blepharitis); history of
inadequate adherence; intolerance or
contraindication to either prostaglandins,
b-blockers, dorzolamide, or BAK; severe OSD,
intraocular conventional or laser surgery in the
study eye (within 6 months prior to
enrollment); previous history of ocular trauma;
use of oral or topical corticosteroids (within
3 months before the enrollment), and use of
contact lenses. Additional exclusion criteria
were clinical evidence of inflammation, signs
of any corneal abnormality precluding reliable
IOP measurements, and unwillingness to
participate in the trial. Women of childbearing
potential and lactating mothers were also
excluded.
Eligible participants first underwent a
latanoprost-treated 24-h IOP assessment
together with an ocular surface evaluation (as
described in a following section). Study patients
were then randomized to either PF tafluprost
monotherapy (Saflutan, Santen Oy, Tampere,
Finland) dosed in the evening (21:00) or PF
tafluprost administered once in the evening
(21:00) and preservative-free DTFC (Cosopt PF,
Santen, Santen Oy, Tampere, Finland) dosed
twice daily (08:00 and 20:00). A 1-h deviation
from prescribed administration time was
allowed for the instillation of study
medications. After 3 months (±2 weeks) of
therapy all participants underwent a second,
treated 24-h IOP assessment and a second
ocular surface evaluation. Study participants
were then switched to the opposite regimen
and after another 3 months (±2 weeks) of
therapy they underwent a final treated
evaluation of 24-h IOP and ocular surface
status. Instructions regarding correct eye-drop
instillation and adherence were repeated at
every visit.
Procedures
All study patients underwent habitual 24-h IOP
monitoring (i.e., with Goldmann applanation
tonometry measuring sitting IOP at 10:00,
14:00, 18:00, 22:00 and with Perkins
tonometry measuring supine IOP values at
02:00 and 06:00). Nighttime supine IOP
measurements were performed 5 min after the
patients were awakened. The same masked
investigators performed all IOP measurements
using the same calibrated instruments. A
comprehensive clinical examination was
performed at all visits. Ocular surface health
was evaluated before any IOP measurement
using well-established clinical signs (described
below) in accordance with the guidelines and
methodology proposed by the International
Dry Eye Workshop and Meibomian Gland
Dysfunction Workshop [26, 27]. Additionally,
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patient-reported complaints and symptoms as
well as investigator-noted adverse events were
recorded at the end of each treatment period.
Ocular Surface Assessment
After recording any self-reported ocular surface
symptoms, we performed the following tests:
1. Tear film break-up time (TFBUT). A small
quantity of fluorescein was instilled into the
inferior fornix with the use of a
fluorescein-impregnated paper strip soaked
with a drop of unpreserved normal saline.
After a few blinks the patient was instructed
to keep the eyelids open and the interval
between the last complete blink and the
first appearance of a dry spot, or disruption
of the tear film viewed with the use of a
cobalt blue filter, was recorded.
2. Corneal fluorescein staining. Following the
TFBUT test, the cornea was examined for
punctate epitheliopathy staining with
fluorescein. The pattern and density of the
spots were evaluated with the van
Bijsterveld grading method using a range
of 0–3 [28].
3. Schirmer I test (without anesthesia). The
test provides an estimation of reflex tear
flow stimulated by the insertion of a filter
paper into the conjunctival sac at the
junction between the lateral and middle
third of the lower eyelid. The length of
paper in millimeters soaked by tears within
5 min was recorded in each case.
Statistics
The primary efficacy endpoint of this trial was
the mean 24-h IOP (the average pressure for the
six time points). The individual time points,
peak, trough, and fluctuation of 24-h IOP were
considered secondary endpoints. A mixed
model was used for the crossover repeated
measures design to adjust for period and
carry-over effects. Period and sequence were
included in the model as fixed effects. Patients
within a sequence were included in the model
as a random effect. A 95% confidence interval
(CI) was constructed for the adjusted difference
in means. An intention-to-treat approach was
adopted and the subjects were analyzed
according to their randomized group.
The current 24-h study had an 80% power
to identify a 1.25-mmHg difference between
individual time points and between mean 24-h
pressure readings assuming a standard
deviation of 2.8 mmHg between treatments if
42 patients completed the trial. When both
eyes qualified for inclusion, the worse eye (i.e.,
the one with the higher IOP at baseline) was
selected. Mean 24-h IOP fluctuation (average of
the highest minus the lowest IOP for each
individual patient) as well as the mean peak
and trough pressures were analyzed by the
paired t test. Ocular surface signs after each
treatment period were compared with the
paired t test. Adverse events were evaluated
using Cochran’s Q and McNemar’s tests. The
Bonferroni-adjusted P values are reported to
correct for multiple comparisons in secondary
endpoints. All other reported P values are
two-tailed with P\0.05 considered
significant. Analyses were conducted using




Forty-three open-angle glaucoma patients (22
women and 21 men) completed the study out of
45 enrolled (Fig. 1). There were 24 patients with
exfoliative glaucoma, 18 with primary
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open-angle glaucoma, and one with pigmentary
glaucoma. The mean ± SD age of participants
was 66.4 ± 12.3 years. Sixteen patients were
using generic latanoprost whereas 27 were
using branded latanoprost.
Intraocular Pressure
The mean untreated morning IOP of the study
cohort was 30.6 mmHg and the mean 24-h
latanoprost-treated baseline IOP was
22.2 ± 2.9 mmHg (Table 1). PF tafluprost
obtained lower IOP compared to latanoprost at
two night-time points: 02:00 (P = 0.027) and
06:00 (P\0.001) (Table 1, Fig. 2). Moreover, PF
tafluprost reduced mean 24-h IOP to a greater
extent than preserved latanoprost (21.9 vs
22.2 mmHg; P = 0.006). A greater reduction
with PF tafluprost was also established with
regard to peak 24-h IOP (23.9 vs 24.5 mmHg;
P = 0.001) and 24-h IOP fluctuation (3.9 vs
4.6 mmHg; P = 0.001); (Table 1, Fig. 2).
Triple PF therapy, comprising PF tafluprost
and PF DTFC, provided significantly better 24-h
IOP characteristics than preserved latanoprost
or PF tafluprost monotherapies. Compared to
preserved latanoprost the triple regimen
significantly reduced IOP at all individual time
24-hour IOP on latanoprost + OSE
24-hour IOP measurement + OSE
24-hour IOP measurement + OSE
45 open-angle glaucoma patients insufficiently controlled on BAK-preserved 
latanoprost monotherapy who also exhibited signs, or symptoms of ocular 
surface disease enrolled 
(2 patients lost to follow up)
PF tafluprost for 3 months 
(n=22)
PF tafluprost and PF DTFC for 
3 months (n=21)
PF tafluprost and PF DTFC 
for 3 months (n=22)
PF tafluprost for 3 
months (n=21)
Adverse events were recorded at the end of each treatment period
Fig. 1 Flowchart of the study. BAK benzalkonium
chloride, DTFC dorzolamide/timolol ﬁxed combination,
OSE ocular surface evaluation
Table 1 Efﬁcacy comparisons between preserved latanoprost and PF taﬂuprost
Time/IOP parameter Latanoprost (mmHg) Taﬂuprost (mmHg) P value
06:00 22.5 ± 3.8 21.9 ± 3.7 \0.001*
10:00 22.8 ± 3.0 22.7 ± 3.6 1.0*
14:00 21.5 ± 2.6 21.9 ± 3.0 0.468*
18:00 22.5 ± 3.2 22.2 ± 3.4 1.0*
22:00 22.2 ± 3.9 21.7 ± 3.8 0.126*
02:00 21.6 ± 3.2 21.1 ± 3.5 0.027*
Mean 24-h IOP 22.2 ± 2.9 21.9 ± 3.2 0.006
Trough 24-h IOP 19.9 ± 2.7 20.1 ± 2.8 0.421
Peak 24-h IOP 24.5 ± 3.3 23.9 ± 3.5 0.001
24-h ﬂuctuation 4.6 ± 1.6 3.9 ± 1.3 0.001
Results are presented as mean ± standard deviation
* Bonferroni-adjusted P values
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points, mean 24-h IOP (17.3 vs 22.2 mmHg),
trough 24-h IOP (15.3 vs 19.9 mmHg), and peak
24-h IOP (19.8 vs 24.5 mmHg) (all P\0.001;
Table 2, Fig. 2). A similar picture emerged when
the triple PF therapy was compared with PF
tafluprost (Table 3, Fig. 2).
It is worth noting that both prostaglandin
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Fig. 2 24-h IOP control with BAK-preserved latanoprost (red), preservative-free taﬂuprost (green), and combined PF triple
therapy (taﬂuprost and dorzolamide/timolol ﬁxed combination) (yellow)
Table 2 Efﬁcacy comparisons between preserved latanoprost baseline and triple PF therapy regimen (taﬂuprost and
dorzolamide/timolol ﬁxed combination)
Time/IOP parameter Latanoprost (mmHg) Triple therapy (mmHg) P value
06:00 22.5 ± 3.8 18.2 ± 3.7 \0.001*
10:00 22.8 ± 3.0 17.0 ± 3.1 \0.001*
14:00 21.5 ± 2.6 17.1 ± 2.8 \0.001*
18:00 22.5 ± 3.2 17.1 ± 3.2 \0.001*
22:00 22.2 ± 3.9 16.7 ± 3.1 \0.001*
02:00 21.6 ± 3.2 18.0 ± 3.0 \0.001*
Mean 24-h IOP 22.2 ± 2.9 17.3 ± 2.7 \0.001
Trough 24-h IOP 19.9 ± 2.7 15.3 ± 2.6 \0.001
Peak 24-h IOP 24.5 ± 3.3 19.8 ± 3.4 \0.001
24-h ﬂuctuation 4.6 ± 1.6 4.4 ± 2.3 0.726
Results are presented as mean ± standard deviation
* Bonferroni-adjusted P values
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daytime IOP (22.3 mmHg) (Fig. 3). However,
the reason for the statistical difference
between PF tafluprost and latanoprost in this
study was due to a greater nighttime efficacy
of PF tafluprost (21.5 vs 22.1 mmHg;
P\0.001). Finally, the triple PF therapy
regimen offered significantly lower daytime
and nighttime IOP than either preserved
latanoprost or PF tafluprost (P\0.001 for all
comparisons).
Table 3 Efﬁcacy comparisons between PF taﬂuprost and triple PF therapy (taﬂuprost and dorzolamide/timolol ﬁxed
combination)
IOP parameter Taﬂuprost (mmHg) Triple therapy (mmHg) P value IOP change (%)
06:00 21.9 ± 3.7 18.2 ± 3.7 \0.001* -16.9
10:00 22.7 ± 3.6 17.0 ± 3.1 \0.001* -25.2
14:00 21.9 ± 3.0 17.1 ± 2.8 \0.001* -22.0
18:00 22.2 ± 3.4 17.1 ± 3.2 \0.001* -23.0
22:00 21.7 ± 3.8 16.7 ± 3.1 \0.001* -23.1
02:00 21.1 ± 3.5 18.0 ± 3.0 \0.001* -14.7
Mean 24-h IOP 21.9 ± 3.2 17.3 ± 2.7 \0.001 -21.1
Trough 24-h IOP 20.1 ± 2.8 15.3 ± 2.6 \0.001 -23.9
Peak 24-h IOP 23.9 ± 3.5 19.8 ± 3.4 \0.001 -17.2
24-h ﬂuctuation 3.9 ± 1.3 4.4 ± 2.3 0.04 ?12.8
Results are presented as mean ± standard deviation
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Fig. 3 Daytime (orange) and nighttime (blue) efﬁcacy of the study medications
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Ocular Surface Assessment
Overall, PF tafluprost was associated with
significantly better ocular surface parameters
than preserved latanoprost (TFBUT, 6.7 vs 6.0;
corneal stain, 1.3 vs 2.2, Schirmer I test, 9.1 vs
8.2, respectively; P\0.01 for all comparisons)
(Table 4). Triple therapy was statistically
similar to latanoprost with regard to TFBUT
and Schirmer tests but was significantly better
than latanoprost with regard to corneal
staining (1.7 vs 2.2; P\0.001) (Table 4). On
the other hand, PF tafluprost monotherapy
demonstrated significantly better ocular surface
parameters compared to triple PF therapy
(P\0.01 for all comparisons) (Table 4). These
findings suggest that PF tafluprost
monotherapy is associated with a healthier
ocular surface as opposed to either
BAK-preserved latanoprost monotherapy or a
triple PF regimen. The latter observation is not
surprising since a triple PF regimen can have a
more negative impact upon the ocular surface
than a PF monotherapy as a result of the effect
of multiple instillations with three different
active ingredients compared with only one.
Table 4 Comparison of ocular surface signs with preserved latanoprost, PF taﬂuprost, and triple PF therapy (taﬂuprost and
dorzolamide/timolol ﬁxed combination)








2.2 ± 0.7 1.3 ± 0.6* 1.7 ± 0.6*
Schirmer test (mm) 8.2 ± 4.7 9.1 ± 4.4* 8.2 ± 4.5
Break-up time (s) 6.0 ± 2.2 6.7 ± 2.2* 6.1 ± 2.3
An asterisk denotes a statistically signiﬁcant difference (P\0.001) vs latanoprost baseline. All three ocular surface
parameters were also signiﬁcantly better (P\0.001) with PF taﬂuprost vs triple PF therapy
SD standard deviation
Table 5 Comparison of the most clinically important/commonest adverse events recorded with preserved latanoprost, PF
taﬂuprost, and triple PF therapy (taﬂuprost and dorzolamide/timolol ﬁxed combination)
Adverse event Latanoprost n (%) Taﬂuprost n (%) Triple therapy n (%) P value
Tired eyes 4 (9.3) 0 (0) 0 (0) 0.018
Fluctuating vision 4 (9.3) 0 (0) 0 (0) 0.018
Burning 0 (0) 0 (0) 3 (6.9) 0.05
Stinging 2 (4.6) 3 (6.9) 9 (20.9) 0.028
Bitter taste 0 (0) 0 (0) 5 (11.6) 0.007
Hyperemia 8 (18.6) 5 (11.6) 4 (9.3) 0.074
Itchiness 5 (11.6) 3 (6.9) 1 (2.3) 0.091
Ocular ache 2 (4.6) 0 (0) 0 (0) 0.135
Blurring of vision 4 (9.3) 3 (6.9) 2 (4.6) 0.368
Total number of adverse events 56 34 55 \0.001
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Adverse Events
All three study regimens were well tolerated
(Table 5). It is worth noting, however, that PF
tafluprost demonstrated a significantly smaller
meannumber of adverse events (0.77) than either
preserved latanoprost (1.42) or the triple PF
therapy regimen (1.37) (P\0.001 for both
comparisons). The mean number of adverse
events observed with preserved latanoprost was
statistically similar to that seen with triple PF
therapy (P = 0.65). Specifically, study subjects
reported a significantly greater prevalence of
tired eyes (9.3%) or fluctuating vision (9.3%)
with preserved latanoprost compared to PF
tafluprost (0%) or triple PF therapy (0%)
(P = 0.018 for both comparisons; Table 5).
Conversely, burning (6.9%), stinging (20.9%),
and bitter taste (11.6%) were significantly more
commonwith the triple PF therapy regimen than
either latanoprost or tafluprost monotherapies.
DISCUSSION
To the best of our knowledge this is the first study
to compare the 24-h efficacy and ocular surface
status with a triple PF regimen versus a popular
monotherapy: BAK-preserved latanoprost in a
cohort of open-angle glaucoma patients. This
study also evaluated the same parameters after
switching from preserved latanoprost to PF
tafluprost monotherapy. It should be noted that
all participants were insufficiently controlled on
preserved latanoprost monotherapy and also
exhibited signs or symptoms of OSD. We opted
for a complete 24-h IOP assessment, as previous
researchhas shownconclusively that such studies
offer a comprehensive evaluation of the true
efficacy of available treatment options [29–32].
Lifelong topical antiglaucoma therapy with
preservedmedications has a detrimental effect on
ocular surface health, especially when multiple
agents are used. Currently, there is limited
controlled evidence pertaining to the health of
the ocular surface with chronic combined
antiglaucoma therapy [33]. In the present study
we employed three easy-to-perform clinical
ocular surface metrics: the TFBUT, corneal
staining, and the Schirmer test. Although these
tests may at times show suboptimal consistency
and reliability they are still the mainstay of
clinical tests used to detect and quantify
epithelial and tear film abnormalities [34].
The 24-h efficacy results of the present trial
first suggest that switching from preserved
latanoprost to PF tafluprost monotherapy in
glaucoma patients with symptoms/signs of OSD
attains a statistically significant IOP reduction
at the 06:00 and 02:00 time points as well as for
the mean, peak, and fluctuation of 24-h IOP.
The comparison between mean daytime and
nighttime IOP control with the two
prostaglandins highlights the point that while
both medications obtain identical daytime IOP
(22.3 mmHg) PF tafluprost is more efficient at
night (21.5 vs 22.1 mmHg; P\0.001). This
observation is consistent with previous 24-h
evidence indicating that PF tafluprost displays
superior nighttime efficacy compared to
latanoprost [35]. In our study, the 24-h
efficacy difference between preserved
latanoprost and PF tafluprost was 0.3 mmHg.
Although this efficacy difference was
statistically significant it may not be clinically
meaningful. This is because the potential
clinical value of a 24-h efficacy difference
remains to be elucidated. On the other hand,
there may be a long-term advantage because PF
tafluprost provided significantly lower peak
24-h IOP and a significantly narrower 24-h
IOP fluctuation. There is emerging evidence
that these 24-h parameters (especially peak 24-h
IOP) are associated with a better long-term
prognosis [36–41].
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Triple PF regimen demonstrated superior
efficacy compared to the two prostaglandins at
all individual time points, and for the mean,
peak, and trough 24-h IOP (all P\0.001). Since
the observed 24-h difference is considerable
(compared to latanoprost baseline a 4.9 mmHg
or 22.1% reduction) it is clear that such an
efficacy difference is not only statistically
significant but also clinically meaningful in
the stepwise management of glaucoma. Thus,
the results of the present study suggest that
when monotherapies are insufficient and a
substantial IOP lowering is needed the triple
PF regimen employed herein may represent a
suitable option to attain good efficacy together
with good tolerability.
As expected, the triple PF regimen was also
significantly more efficacious than PF tafluprost
monotherapy for all comparisons except 24-h
fluctuation. It is of interest that PF tafluprost
monotherapy achieved a significantly lesser 24-h
IOP fluctuation than the triple PF regimen (3.9 vs
4.4 mmHg; P = 0.04). This could be due to a less
uniform pattern of IOP reduction by DTFC.
Owing to the presence of timolol, the additional
ocular hypotensive effect was more pronounced
during the day than during the night, thus
generating a greater fluctuation of treated 24-h
IOP. This confirms previously published 24-h
evidence [29, 42] that shows that 24-h IOP
fluctuation with combined therapy is either the
same or slightly worse than that obtained with
prostaglandin monotherapies. Moreover, the
present study highlights the fact that the true
efficacy of PF tafluprost and the triple PF regimen
would have remained undetected without a
complete 24-h evaluation. Since 24-h
monitoring is impractical for the vast majority
of glaucoma patients in routine care, we should
rely on published controlled 24-h evidence to
facilitate management decisions in glaucoma
therapy [29–32, 35].
A key consideration beyond efficacy in
chronic, asymptomatic diseases like glaucoma
is the long-term tolerability of glaucoma
therapies. Long-term tolerability can affect
adherence, efficacy, and ultimately therapeutic
success and prognosis. Consequently, the
long-term impact of glaucoma medications on
ocular surface health should be taken into
account in all therapeutic algorithms
[6, 10, 13]. In the present trial a similar total
number of adverse events was observed with
preserved latanoprost and triple PF therapy. In
contrast, significantly fewer adverse events were
recorded with PF tafluprost. These results
suggest that PF treatment options can
certainly improve tolerability in a group of
glaucoma patients with symptoms or signs of
OSD. To monitor the health of the ocular
surface with the three regimens in our study,
we employed three popular metrics (TFBUT,
corneal stain, and Schirmer test). Compared to
BAK-preserved latanoprost, PF tafluprost was
associated with significantly better scores in all
three tested parameters, indicating a significant
improvement in terms of ocular surface health.
On the other hand, the triple PF regimen
demonstrated significantly less corneal staining
score and similar TFBUT and Schirmer test
scores compared to BAK-preserved latanoprost.
It was surprising that a combination of three PF
daily drops containing three different active
ingredients demonstrated a similar ocular
surface profile and comparable tolerability to a
well-known reference prostaglandin
monotherapy (i.e., preserved branded or
generic latanoprost). This is likely due to the
elimination of BAK, but could also be attributed
to the relatively small sample size (43 patients)
or the short duration of the study (3 months).
Moreover, to better reflect clinical practice the
study cohort was preselected for having
symptoms or signs of OSD and showing
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insufficient IOP control with latanoprost
monotherapy. Nevertheless, it is well
established that the majority of glaucoma
patients demonstrate OSD and most glaucoma
patients will require adjunctive therapy
[1, 6, 9, 13].
The triple PF regimen employed in this study
can conceivably be considered a logical maximal
medical therapy option for many patients. This
implies that to succeed with long-term therapy
such an option should be as tolerable as possible.
It should be emphasized, however, that the
short-term tolerability of antiglaucoma
medications does not necessarily mirror
long-term tolerability. In fact, it is reasonable
to assume that in contrast to PF treatment
options, the tolerability of BAK-containing
medications would decrease over the long term
because of the cumulative toxic effect of the
preservative on the ocular surface.
Certain limitations of this study need to be
taken into account. Firstly, we did not employ
sophisticated and possibly more accurate metrics
for the evaluationof theocular surface. Instead, to
better reflect standard clinical practiceworldwide,
we opted for the three most commonly used tests
in daily practice (i.e., TFBUT, corneal stain, and
Schirmer I test). Promising research avenues
include assessment of patient symptoms with
validated questionnaires, tear film quality and
quantity valuation by means of osmolarity
measurements, and assessment of the ocular
surface damage with lissamine green. Ideally,
meibomian gland morphology and function
tests should also be included [26, 27]. Finally,
once validated, novel tests such as the
measurement of matrix metalloproteinase-9
(MMP-9) [43], ocular surface epithelium
impression cytology [44], and electronic
assessment of tear film properties [45], which
objectively characterize the tear film and image
in vivo ocular surface tissues, may prove
instrumental in future research [46]. Another
limitation of the present study is that we did not
evaluate the long-term benefits or the health
outcome with PF medications. The detection of
significant differences, however, in terms of 24-h
efficacy and ocular surface health with the
short-term use of the PF medications
investigated herein, lends support to the
hypothesis that clear-cut differences should
emerge over the long term, too. This assumption
requires further validation. Lastly, this study
included glaucoma patients insufficiently
controlled with preserved branded or generic
latanoprost who exhibited signs or symptoms of
OSD. It remains unclear what impact (if any) the
inclusion of glaucoma patients treated with
generic latanoprost formulations (four
formulations employed in 16/43 of our patients)
had. This approach, however, was selected to
reflect current clinical practice.
Overall the present investigation established
that in glaucoma patients with symptoms or
signs of OSD insufficiently controlled on
preserved latanoprost, PF tafluprost provides
greater 24-h efficacy and enhances ocular
surface health and tolerability. A triple PF
regimen comprising tafluprost and DTFC
provides superior 24-h IOP control compared
with preserved latanoprost or PF tafluprost. The
ocular surface profile of the triple PF regimen
was found to be similar to that of BAK-preserved
latanoprost.
CONCLUSION
In the present crossover study eligible glaucoma
patients who demonstrated symptoms or signs
of OSD on preserved branded or generic
latanoprost were switched to PF tafluprost
therapy and a triple PF regimen consisting of
PF tafluprost and PF DTFC. Treatment with PF
tafluprost not only offered statistically lower
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mean, peak, and fluctuation of 24-h IOP but
also enhanced ocular surface parameters and
tolerability. The triple PF regimen provided
significantly better 24-h IOP control (-22%)
than latanoprost baseline therapy. These results
suggest that PF treatment options can
meaningfully improve tolerability in glaucoma
patients with symptoms or signs of OSD.
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